Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing

Series C financing brings total capital raised in the last 12 months to over US$ 400 million (>RMB 2.5 billion) The proceeds will support the continued development and expansion of Clover’s pipeline of protein-based vaccines and biologic cancer therapies CHENGDU, CHINA, February 23, 2021—Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics as vaccines …

Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing Read More »

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021 CHENGDU, China, February 1, 2021—Clover Biopharmaceuticals …

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet Read More »

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021 The Coalition for Epidemic Preparedness Innovations (CEPI) continues to support Clover’s COVID-19 …

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate Read More »

Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates

Clover’s protein-based COVID-19 vaccine candidates adjuvanted with either GSK’s pandemic adjuvant system or Dynavax’s CpG 1018 plus alum induced strong neutralizing immune responses in 150 adult and elderly subjects from the Phase 1 clinical study.  Clover’s vaccine candidates both demonstrated a favorable safety and tolerability profile, and have also shown long-term stability at 2-8oC, making them …

Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates Read More »

CEPI extends partnership with Clover Biopharmaceuticals to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure

CEPI to fund the development of Clover’s protein-based S-Trimer vaccine candidate through to licensure, including a global pivotal Phase 2/3 efficacy clinical study beginning before the end of 2020. Agreement between CEPI and Clover anticipates that the vaccine – if proven to be safe and effective – will be made available for procurement and allocation …

CEPI extends partnership with Clover Biopharmaceuticals to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure Read More »

Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program

SAB to provide strategic guidance for the global development of Clover’s COVID-19 vaccine program Comprised of prominent vaccine and industry experts from around the world CHENGDU, CHINA, September 25, 2020 – Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, today announced the formation of its Scientific …

Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program Read More »

Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate

Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animals and protects nonhuman primates from SARS-CoV-2 challenge Strong immune response and protection observed with adjuvant systems from GSK and Dynavax led to inclusion of both adjuvants separately into Clover’s ongoing Phase 1 clinical trial of S-Trimer Clover’s …

Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate Read More »

CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate

CEPI to invest an additional $66m upfront in Clover’s S-Trimer protein vaccine candidate. Funding will support clinical development in parallel with scale-up of manufacturing capacity to potentially produce hundreds of millions of doses per year. OSLO, NORWAY, July 8, 2020—CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the expansion of its partnership with Sichuan …

CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate Read More »

Clover Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate

150 healthy adult and elderly participants expected to be enrolled in Phase 1 study COVID-19 vaccine candidate to be evaluated in combination with GSK’s pandemic adjuvant system and Dynavax’s CpG 1018 adjuvant following promising preclinical study results Preliminary safety and immunogenicity results expected in August 2020 Global Phase 2b/3 vaccine efficacy study is in planning …

Clover Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate Read More »

GL Ventures Completes $24 Million Series B-2 Investment in Clover Biopharmaceuticals

BEIJING, CHINA, June 8, 2020 – Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced the completion of a US$ 24 million Series B-2 financing from GL Ventures. This financing round brings Clover’s total capital raised since 2016 to over US$ 140 million. “We are pleased to …

GL Ventures Completes $24 Million Series B-2 Investment in Clover Biopharmaceuticals Read More »